Henning T. Mouridsen

TL;DR: The rates of recurrent disease are lower in all subsets of patients treated with tamoxifen, but are only statistically significant in patients 50–59 years of age or with 4 or more positive lymph nodes.

TL;DR: No differences were observed between the two prednimustine‐treated groups, whereas the group treated with chlorambucil plus prednisolone experienced a significantly higher degree of leukopenia and/or thrombopenia, and should be compared to other alkylating agents in patients with advanced breast cancer in randomized trials.

TL;DR: This study provides the most comprehensive description of HRQL in adjuvant therapy to date and indicates that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.

TL;DR: Regardless of schedule and dose, epi is not superior to dox in the treatment of patients with advanced soft tissue sarcomas, and the results illustrate that the data from small studies of single institutions should always be confirmed by large multi-institutional studies before being taken for granted.

TL;DR: This small sub-study supports the hypothesis that letrozole is superior to tamoxifen primarily in patients expressing high levels of estrogen regulated proteins in the primary tumor tissue, and shows that the “ER activity profile” with high PR, IGF-IR and Bcl-2 is a promising selection criterion, regarding prediction of response to letroZole versus tamoxIFen therapy.